Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439089 | 0.97 | PIK3CD (0.41) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL9898649 | 0.96 | EPHX2 (0.38) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1438609 | 0.95 | KDM5A (0.36) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1439010 | 0.94 | KDM5A (0.38) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1439184 | 0.94 | KDM5A (0.37) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL9897296 | 0.93 | EPHX2 (0.38) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1439230 | 0.92 | KDM5A (0.36) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1439034 | 0.92 | KDM5A (0.38) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1439190 | 0.91 | KDM5A (0.39) | PIK3CDPIK3CAPIK3R1KDM5AEPHX2 | |
| SCHEMBL9898443 | 0.91 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | claimed |
| EP-2470536-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2012-07-04 | — | — | EP | claimed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | claimed |
| WO-2011023693-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-03-03 | — | — | WO | claimed |
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| EP-2470536-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023693-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | PIK3CD 888/4885PIK3CA 691/4885PIK3R1 2369/4885 |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE12, PDE5A, PDE4A | PIK3CD 1051/4885PIK3CA 818/4885PIK3R1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.